Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

The results are a boost to Novo Nordisk after another weight-loss therapy, CagriSema (cagrilintide and semaglutide), delivered lower-than-hoped-for weight loss of 20.4% at 68 weeks in a phase 3 ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...